Infarct size reduction by cyclosporine A at reperfusion involves inhibition of the mitochondrial permeability transition pore but does not improve mitochondrial respiration

Nilguen Gedik, Gerd Heusch, Andreas Skyschally

Institut für Pathophysiologie, Universitätsklinikum Essen, Essen, Germany

Submitted: 12 July 2013
Accepted: 2 September 2013

Arch Med Sci 2013; 9, 6: 968–975
DOI: 10.5114/aoms.2013.38175
Copyright © 2013 Termedia & Banach

Abstract

Introduction: Ischemic postconditioning (PoCo) and cyclosporine A (CysA) given prior to reperfusion reduce myocardial infarct size after ischemia/reperfusion. Ischemic postconditioning’s protection is characterized by better preservation of mitochondrial respiration and calcium retention capacity. Protection by CysA is not entirely clear. Cyclosporine A inhibits not only mitochondrial permeability transition pore (mPTP) opening but also the phosphatase calcineurin. We have investigated whether CysA mediates protection not only by mPTP inhibition but also through a more upstream inhibition of calcineurin with subsequently better preserved mitochondrial respiration.

Material and methods: Anesthetized pigs were subjected to 90 min ischemia and 10 min reperfusion initiated with either PoCo (6 × 20 s reperfusion/re-occlusion; n = 9), CysA infusion (5 mg/kg i.v.; 5 min before reperfusion; n = 4), or immediate full reperfusion (IFR; n = 8). Mitochondria were isolated from myocardial tissue for measurement of respiration and calcium retention capacity.

Results: In mitochondria from ischemic/reperfused myocardium, ADP-stimulated complex I respiration was similar between CysA (116 ±11 nmol O2/min/mg protein) and IFR (117 ±8), but better preserved with PoCo (160 ±9; p < 0.05). Calcium retention capacity was greater with both PoCo and CysA (1096 ±45 and 1287 ±128 nmol Ca2+/mg protein) than with IFR (756 ±103; p < 0.05).

Conclusions: Cyclosporine A’s protection is not associated with improved mitochondrial respiration. Protection is unlikely related to an upstream calcineurin inhibition, but is indeed secondary to mPTP inhibition.

Key words: cyclosporine A, infarct size, ischemic postconditioning, mitochondrion, myocardial ischemia/reperfusion.

Introduction

Timely restoration of blood flow is mandatory to salvage ischemic myocardium from irreversible damage; however, reperfusion induces additional damage, i.e. reperfusion injury, and contributes to final infarct size [1–3].

Ischemic postconditioning (PoCo) – i.e. brief episodes of intermittent coronary re-occlusion during early reperfusion – and gentle reperfusion – i.e. slow restoration of coronary blood flow – protect myocardium from reperfusion injury [4, 5]. Attenuation of reperfusion injury and thus reduction of final infarct size can also be achieved pharmacologically...
Infarct size reduction by cyclosporine A at reperfusion involves inhibition of the mitochondrial permeability transition pore but does not improve mitochondrial respiration.
ter preserved mitochondrial respiration after ischemia/reperfusion. Indeed, with cardioprotection by PoCo, the better preserved mitochondrial complex I respiration is causally linked to increased phosphorylation of signal transducer and activator of transcription 3 (STAT3) in pig cardiomyocyte mitochondria [25].

Calcineurin inhibition might also be associated with protection of mitochondria. The regulatory subunit calcineurin B is present in mitochondria from rat kidneys [26], and calcineurin dephosphorylates the pro-apoptotic protein Bad [27] and enables its translocation into cardiomyocyte mitochondria [28]. Cell death induced by stimulation of rat cardiomyocytes with the β-adrenergic agonist isoproterenol is secondary to dephosphorylation of Bad and is inhibited by CysA or the selective calcineurin inhibitor FK506 [29]. In cardiomyocytes isolated from dogs with heart failure, CysA treatment improves mitochondrial respiration [30].

To elucidate whether an improvement of mitochondrial function by CysA is mediated not only by mPTP inhibition but also by a more upstream mechanism through calcineurin inhibition with subsequent better respiration, we have used our established and clinically relevant in situ model in anesthetized pigs [31].

In this experimental model infarct size is reduced by both PoCo and administration of CysA prior to reperfusion [10, 25]. In the present study we subjected pigs to the same experimental protocols as in those previous studies, but now measured mitochondrial respiration and calcium retention capacity of cardiomyocyte mitochondria harvested at 10 min reperfusion.

Material and methods

The experimental protocols were approved by the Bioethical Committee of the district of Düsseldorf, Germany, and the investigation conforms to the Guide for the Care and Use of Laboratory Animals published by NIH Publication 85-23, revised 1996.

Experimental preparation and protocols

Göttinger minipigs (20–40 kg) of either sex were sedated using ketamine hydrochloride (1 g intramuscularly). Anesthesia was induced by thiopental (500 mg intravenously) and maintained using enflurane (1.5–2.0%) with an oxygen/nitrous oxide mixture (40 : 60%). We used an open-chest pig preparation with controlled hypoperfusion of the left anterior descending coronary artery (LAD) perfusion territory through an extracorporeal circuit [31]. Coronary inflow of the LAD was reduced to 10% of baseline flow and maintained constant at this level for 90 min. Reperfusion was initiated with a PoCo maneuver (6 cycles of 20 s re-occlusion/reperfusion; n = 9) or infusion of CysA (5 mg/kg i.v.; n = 4) 5 min before the onset of reperfusion. Due to the slightly higher viscosity of the CysA solution it had to be given slowly over 3–4 min. To ensure that the complete dosage of CysA had become evenly distributed in the circulation with the beginning of reperfusion, the CysA infusion was started 5 min before reperfusion. Pigs subjected to immediate full reperfusion (n = 8) served as controls. The experiments were terminated at 10 min reperfusion for tissue sampling (6–10 g) from the area at risk and a remote control zone as an intra-individual control. The time point of 10 min reperfusion was chosen in accordance with our previous studies on cardioprotection by PoCo [25, 32].

Infarct size

Unlike our previous study [10] in which we focused on infarct size reduction by PoCo or CysA, infarct size in the present study was not measurable due to tissue sampling at 10 min reperfusion for mitochondrial isolation. However, the same in situ pig model, the same protocols and the same drug administration scheme were used in the present study; thus, for infarct size reduction with CysA and PoCo we refer to our previous study [10].

Isolation of mitochondria

Samples were cleaned of adipose tissue and large vessels, minced and then homogenized (Ultra-Turrax, IKA, Staufen, Germany; 2 × 10 s at a shaft rotation rate of 6,500 rpm and 1 × 5 s at 9,500 rpm) in ice-cold isolation buffer (in mmol/l: sucrose 250; HEPES 10; EGTA 1, pH 7.4). Bovine serum albumin (BSA; 5 mg/ml) was added only during the mincing and homogenizing procedures. The homogenate was centrifuged at 700 g for 10 min. The supernatant was collected and centrifuged at 14,000 g for 10 min. The resulting pellet was resuspended in isolation buffer and centrifuged at 10,000 g for 5 min. This procedure was repeated, and the final mitochondrial pellet was resuspended in an appropriate volume of isolation buffer to get a stock suspension with a protein concentration of about 10 µg/µl. All procedures were performed on ice or at 4°C (centrifugation).

The protein concentration of the isolated mitochondria was determined with a DC protein assay (BioRad, Hercules, CA, USA) with BSA as standard using the Lowry method [33].

Mitochondrial respiration

The oxygen uptake of 50 µg of mitochondrial protein was measured with a Clark-type electrode (Strathkelvin, Glasgow, UK) at 37°C during magnetic stirring in 0.5 ml of incubation buffer (in mmol/l:...
Infarct size reduction by cyclosporine A at reperfusion involves inhibition of the mitochondrial permeability transition pore but does not improve mitochondrial respiration

125 KCl; 10 MOPS; 5 MgCl₂; 5 KHZPO₄; 0.02 EGTA) with glutamate (5 mmol/l) and malate (5 mmol/l) as substrates. In sequence, basal oxygen consumption and ADP (400 µmol/l)-stimulated respiration were recorded for 3 min each. After that, 300 µmol/l N,N,N,N’-tetramethyl-p-phenylenediamine (T) and 3 mmol/l ascorbate (A) were added to the respiration chamber to determine complex IV respiration. With subsequent addition of 30 nmol/l carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), the maximal oxygen uptake of uncoupled mitochondria was measured. The latter measurements were used as a quality check to prove equal loading of mitochondrial protein in the respiration chamber.

**Calcium retention capacity**

The calcium retention capacity of 100 µg of mitochondrial proteins was determined in 1 ml of incubation buffer (without EGTA) at 37°C using 5 mmol/l glutamate and 5 mmol/l malate in the presence of ADP (400 µmol/l). Calcium green-5N (0.5 µmol/l, Invitrogen, Carlsbad, CA, USA) was used to measure the extramitochondrial calcium concentration with a spectrophotometer (Cary Eclipse, Varian, Mulgrave, Victoria, Australia; excitation/emission wavelengths of 500/530 nm). Aliquots of 5 nmol CaCl₂ were added every minute until cessation of mitochondrial calcium uptake, and a rapid increase in calcium green fluorescence indicated mPTP opening. The small amount of EGTA which is transferred with mitochondria from stock suspension into the cuvette impacted only the first added calcium pulse (tested with mitochondrial free isolation buffer). This offset was similar with each measurement.

**Protein phosphorylation**

Myocardial samples from the area at risk taken at 10 min reperfusion were homogenized and centrifuged. Protein aliquots of 20 µg were electrophoretically separated on 10% SDS-PAGE and transferred to nitrocellulose membranes. After blocking with 5% non-fat dry milk, membranes were incubated with antibodies directed against the phosphorylated forms of AKT, ERK1/2, GSK3β, and STAT3 (phosphorylation sites: tyr705 and ser727). After incubation with the respective secondary anti-rabbit antibodies, immunoreactive signals were detected by chemiluminescence and quantified. Immunoreactivities of phosphorylated proteins were normalized to those of the respective total proteins.

**Statistical analysis**

Data are means ± SEM. Mitochondrial respiration and calcium retention capacity of mitochondria were compared between groups by one-way ANOVA (SigmaStat 3.5, SPSS inc.). Protein phosphorylation was compared by t-tests. Differences were considered significant at the level of p < 0.05.

**Results**

As reported previously, PoCo and CysA given prior to reperfusion reduced infarct size to a similar extent (Figure 2; from [10]).

In the present study, the basal oxygen uptake was not different between groups. Compared to mitochondria from the non-ischemic remote control zone, ischemia/reperfusion attenuated the ADP-stimulated respiration at complex I and maximal uncoupled respiration. With PoCo, the ADP-stimulated complex I respiration was better preserved after ischemia/reperfusion, whereas CysA infusion had no impact on complex I respiration, which was similar to that with immediate full reperfusion (Figure 3). Complex IV respiration as well as maximal uncoupled oxygen uptake was similar between the three groups, indicating even mitochondrial loading of the respiratory chamber (Figure 4).

Calcium retention capacity of mitochondria was reduced in myocardium which had undergone ischemia/reperfusion. Both PoCo and CysA better preserved calcium retention capacity, and an increased calcium retention capacity with CysA was also apparent in mitochondria from the non-ischemic remote control zone (Figure 5).

CysA treatment had no impact on the protein phosphorylation of AKT, ERK1/2, GSK3β, and STAT3 (tyr705 and ser727) in myocardial samples taken from the area at risk at 10 min reperfusion (Figures 6 A–E).

**Discussion**

The notion that myocardial salvage by CysA could also be mediated by an upstream mechanism through calcineurin inhibition and subsequently bet-
ter preservation of mitochondrial respiration is not supported by our results. The general depression of respiration in mitochondria isolated from ischemic/reperfused myocardium may be related to the loss/release of cytochrome C during ischemia/reperfusion [34]. However, at 10 min reperfusion,
a time point at which we have already described changes in mitochondrial respiration, calcium retention capacity and protein phosphorylation related to the PoCo's cardioprotection [25, 32], mitochondrial respiration after ischemia/reperfusion was not improved by CysA, and phosphorylation of cardioprotective proteins was not different from that with ischemia/reperfusion alone (Figures 6 A–E). A few studies have related increased phosphorylation of cardioprotective proteins to calcineurin inhibition. In cardiomyocytes of rats, inhibition of calcineurin by CysA or the selective calcineurin inhibitor FK506 increased the phosphorylation of protein kinase B (AKT) [35]. Calcineurin inhibition by FK506 was also associated with increased phosphorylation of extracellular-signal-regulated kinases 1/2 (ERK1/2) after ischemia, and this interaction mediated the cardioprotection by δ-opioid receptor activation in rats.
Acknowledgments

Supported by the German Research Foundation (He1320/18-1).

References

1. Heusch, G. Postconditioning. Old wine in a new bottle? J Am Coll Cardiol 2004; 44: 1111-2.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35.
3. Ovize M, Baxter GF, Di Lisa F, et al. Postconditioning and protection from reperfusion injury: where do we stand? Cardiovasc Res 2010; 87: 406-23.
4. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2005; 285: H579-88.
5. Musiolik J, van Caster P, Skyschally A, et al. Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. Cardiovasc Res 2010; 85: 110-7.
6. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002; 55: 534-43.
7. Argaud L, Gateau-Roesch O, Muntean D et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005; 38: 367-74.
8. Skyschally A, van Caster P, Ilidromititis EK, Schulz R, Kremastinos DT, Heusch G. Ischemic postconditioning – experimental models and protocol algorithms. Basic Res Cardiol 2009; 104: 469-83.
9. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 2007; 75: 530-5.
10. Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010; 24: 85-7.
11. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. J Mol Cell Cardiol 2008; 43: 195-204.
12. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005; 112: 2143-8.
13. Heusch G. Reduction of infarct size by ischaemic postconditioning in humans: fact or fiction? Eur Heart J 2012; 33: 13-5.
14. Heusch G. Cardioprotection – chances and challenges of its translation to the clinic. Lancet 2013; 381: 166-75.
15. Piot C, Crosillie P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-81.
16. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008; 118: 1915-9.
17. Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection. Basic Res Cardiol 2010; 105: 151-4.
18. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995; 307: 93-8.
19. Cohen MV, Yang XM, Downey JM. Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol 2008; 103: 464-71.
20. Ruiz-Meana M, Insete J, Fernandez-Sanz C, et al. The role of mitochondrial permeability transition in reperfusion-
induced cardiomyocyte death depends on the duration of ischemia. Basic Res Cardiol 2011; 106: 1259-68.

21. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem 2005; 280: 18558-61.

22. Gomez I, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 2008; 117: 2761-8.

23. Di Lisa F, Carpi A, Giorgio V, Bernardi P. The mitochondrial permeability transition pore and cyclophilin D in cardioprotection. Biochim Biophys Acta 2011; 1813: 1316-22.

24. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15.

25. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 2011; 109: 1302-8.

26. Li W, Handschumacher ME. Identification of two calcineurin B-binding proteins: tubulin and heat shock protein 60. Biochim Biophys Acta 2002; 1599: 72-81.

27. Wang HG, Pathan N, Ethell IM, et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999; 284: 339-43.

28. Heineke J, Ritter O. Cardiomyocyte calcineurin signaling in subcellular domains: from the sarcolemma to the nucleus and beyond. J Mol Cell Cardiol 2012; 52: 62-73.

29. Saito S, Hiroi Y, Zou Y, et al. beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem 2000; 275: 34528-33.

30. Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN. Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol 2007; 42: 150-8.

31. Heusch G, Skyschally A, Schulz R. The in-situ pig heart with regional ischemia/reperfusion – ready for translation. J Mol Cell Cardiol 2011; 50: 951-63.

32. Skyschally A, van Caster P, Boengler K, et al. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 2009; 104: 15-8.

33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.

34. Borutaite V, Toleikis A, Brown GC. Inhibition of mitochondrial permeability transition pore by sevoflurane preconditioning in cardiomyocytes: comparison with cyclosporine A. Eur J Pharmacol 2012; 675: 40-6.

35. Oliveira KA, Zecchin KG, Alberici LC, Castillo RF, Versesi AE. Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction. J Bioenerg Biomembr 2008; 40: 307-14.

36. Lehnert BG, Kanemoto S, Matsubara M, et al. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. Ann Thorac Surg 2008; 86: 1286-92.

37. Onishi A, Miyamae M, Kaneda K, Kotani J, Figueredo VM. Direct evidence for inhibition of mitochondrial permeability transition pore by sevoflurane preconditioning in cardiomyocytes: comparison with cyclosporine A. Eur J Pharmacol 2012; 675: 40-6.